Colorectal cancer is typically diagnosed after age 50, but in recent years the disease has been increasingly found in younger people and disproportionately affecting racial and ethnic minorities.

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Your body is a collection of cells carrying thousands of genetic mistakes accrued over a lifetime—many harmless, some bad and ...

Cancer risk in men depends on both genetics and lifestyle, with factors like smoking, diet, and exercise playing significant ...

Short-chain fatty acids influence gene regulation and chromatin accessibility, highlighting their role in colorectal cancer ...

While many people with genetic mutations may never get cancer, these mutations ... breast, uterine, colon and prostate cancers, according to Stadler, who added that this list is not comprehensive.

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...

The KRAS G12C mutation is present in approximately 3-5% of colorectal cancers. Price Action: Amgen stock is up 0.99% at $272.11 at last check Friday.

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC ...